Literature DB >> 18367829

Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?

Ron Ram1, Anat Gafter-Gvili, Elimelech Okon, Idit Pazgal, Ofer Shpilberg, Pia Raanani.   

Abstract

Gelatinous marrow transformation (GMT) is an unusual pathological manifestation of progressive malignant diseases and severe malnutrition states. GMT has been associated with various accelerated hematological malignancies, but has never been described in patients with chronic myelogenous leukemia (CML) treated with imatinib mesylate (IM), a novel tyrosine kinase inhibitor. Herein we report 2 patients with stable chronic phase CML who developed GMT during the course of treatment with IM. A comprehensive review of the relevant published data, several possible mechanisms and therapeutic alternatives are suggested. 2008 S. Karger AG, Basel

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18367829     DOI： 10.1159/000121825

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


  8 in total

1.  Morphologic Changes in the Bone Marrow in Patients of Chronic Myeloid Leukemia (CML) Treated with ImatinibMesylate.

Authors:  B H Srinivas; T Roshni Paul; Shantveer G Uppin; Megha S Uppin; Rachel T Jacob; D Raghunadharao
Journal:  Indian J Hematol Blood Transfus       Date:  2012-01-31       Impact factor: 0.900

2.  Gelatinous transformation of bone marrow following the use of dasatinib in a patient with philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Sanjeev Kumar Sharma; Dharma Choudhary; Anil Handoo; Gaurav Kharya; Nitin Gupta; Punita Pavecha; Ritu Chadha
Journal:  Leuk Res Rep       Date:  2013-01-07

3.  Gelatinous Marrow Transformation in an Imatinib-Treated CML Patient with Pancytopenia Following Severe Sepsis.

Authors:  Pallavi Agrawal; Prashant Sharma; Vikram Narang; Neelam Varma; Pankaj Malhotra; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2012-08-23       Impact factor: 0.900

Review 4.  Hematologic toxicities of small molecule tyrosine kinase inhibitors.

Authors:  Nicholas A Barber; Wais Afzal; Mojtaba Akhtari
Journal:  Target Oncol       Date:  2011-11-30       Impact factor: 4.493

5.  Evaluation of Cytopenias Occurring in Imatinib Treated Chronic Myeloid Leukemia (CML) Patients.

Authors:  T Roshni Paul; Shantveer G Uppin; Megha S Uppin; Rachel T Jacob; D Raghunadha Rao; Senthil J Rajappa
Journal:  Indian J Hematol Blood Transfus       Date:  2010-10-05       Impact factor: 0.900

6.  Gelatinous Marrow Transformation Associated with Imatinib: Case Report and Literature Review.

Authors:  E Chang; G Rivero; B Jiang; S Yellapragada; P Thiagarajan
Journal:  Case Rep Hematol       Date:  2017-01-04

Review 7.  Gelatinous transformation of bone marrow: rare or underdiagnosed?

Authors:  Khushdeep Kaur Shergill; Gagandeep Singh Shergill; Hari Janardanan Pillai
Journal:  Autops Case Rep       Date:  2017-12-08

8.  Ethnic Differences in Hematologic Toxicity from Imatinib in Patients with Gastrointestinal Stromal Cell Tumor (GIST): Coincidence or a Real Phenomenon.

Authors:  Muhammad Wasif Saif; Sneha Purvey; Kristin Kaley; Nawal Wasif; Annmarie Carmel; Teresa Rodriguez; Kenneth B Miller
Journal:  Eurasian J Med Oncol       Date:  2019
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.